Söndag 24 November | 16:55:10 Europe / Stockholm
Svenska | English

IRLAB Therapeutics

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2026-02-11 07:00 Bokslutskommuniké 2025
2025-10-29 07:00 Kvartalsrapport 2025-Q3
2025-07-09 07:00 Kvartalsrapport 2025-Q2
2025-05-21 - Årsstämma
2025-05-07 07:00 Kvartalsrapport 2025-Q1
2025-02-12 07:00 Bokslutskommuniké 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-07-10 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2024-05-22 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-07 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-06-21 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2023-06-20 - Årsstämma
2023-05-10 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2021-05-06 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-08 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2020-05-07 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-06 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-28 - Split IRLAB A 1:5
2019-04-26 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2019-04-25 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-16 - Årsstämma
2017-05-16 - Kvartalsrapport 2017-Q1
2017-02-27 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
IRLAB Therapeutics är ett svenskt forsknings- och läkemedelsbolag. Forskningen utgår ifrån bolagets egna forskningsplattform och är specialiserad mot behandling av hjärnsjukdomar, vanligen benämnt neurodegenerativa sjukdomar. I nuvarande stund har bolaget läkemedelskandidater specialiserade mot bland annat Parkinsons sjukdom. Huvudkontoret ligger i Göteborg.
IRLAB presents at the International Congress of Parkinson's Disease and Movement Disorders®(MDS) 2024
2024-09-25 07:00:00

Gothenburg, Sweden, September 25, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson's disease, today announced that the company will present a poster at this year's edition of the International Congress of Parkinson's Disease and Movement Disorders (MDS), September 27 – October 1, in Philadelphia, USA.

IRLAB's poster describes a meta-analysis of two randomized controlled Phase II trials assessing the efficacy of mesdopetam (IRL790) in levodopa-induced dyskinesia and is entitled “Meta-Analysis of Two Randomized Controlled Trials Assessing the Efficacy of Mesdopetam (IRL790) in Levodopa-Induced Dyskinesia in Parkinson's Disease.”

The poster will be presented by IRLAB’s Director of Clinical Science & Biometrics, Fredrik Hansson, and Susanna Waters, Director of Systems Pharmacology, on 29 September 2024, at 1-3 pm.

Co-authors of the poster are Erik Werner, Nicholas Waters and Joakim Tedroff.

For more information about the conference, please visit https://www.mdscongress.org/

For more information

Kristina Torfgård, CEO
Phone: +46 730 60 70 99
E-mail: kristina.torfgard@irlab.se

About IRLAB

IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Attachments

IRLAB presents at the International Congress of Parkinson's Disease and Movement Disorders®(MDS) 2024

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden